1021913-03-0

Basic information

• Product Name: 7-chloro-6-iodoquinolin-4-ol
• Synonyms: 7-chloro-6-iodoquinolin-4-ol
• CAS NO: 1021913-03-0
• Molecular Formula: C₉H₅ClINO
• Molecular Weight: 305.49957
• Mol File: 1021913-03-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-chloro-6-iodoquinolin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-6-iodoquinolin-4-ol(1021913-03-0)
• EPA Substance Registry System: 7-chloro-6-iodoquinolin-4-ol(1021913-03-0)

Safety Data

• Hazardous Substances Data: 1021913-03-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
7-chloro-6-iodoquinolin-4-ol is utilized as a key intermediate in the development of new pharmaceuticals due to its unique structure and functional groups. Its versatility allows for the creation of diverse drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 7-chloro-6-iodoquinolin-4-ol serves as a valuable building block for the synthesis of complex organic molecules. Its presence of both halogen atoms and the quinoline core makes it a promising candidate for the construction of novel compounds with specific properties.
Used in Antimicrobial Applications:
7-chloro-6-iodoquinolin-4-ol is being studied for its antimicrobial properties, particularly its ability to inhibit bacterial and fungal growth. This makes it a promising candidate for the development of new antibiotics to combat drug-resistant infections.
Used in Anticancer Research:
7-chloro-6-iodoquinolin-4-ol has shown potential as an anticancer agent, and ongoing research is exploring its effectiveness against various types of cancer. Its unique chemical structure may contribute to its ability to target and inhibit cancer cell growth.
Used in Anti-tuberculosis Agents:
As a potential anti-tuberculosis agent, 7-chloro-6-iodoquinolin-4-ol is being investigated for its ability to combat Mycobacterium tuberculosis, the causative agent of tuberculosis. Its development could lead to new treatments for this challenging disease.

Upstream product

• 135050-44-1 3-chloro-4-iodoaniline 
• 1021913-01-8 ethyl 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylate 
• 1021912-99-1 diethyl {[(3-chloro-4-iodophenyl)amino]methylidene}propanedioate 
• 1021913-07-4 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylic acid 

Downstream Products

• 1021913-04-1 3-bromo-7-chloro-6-iodoquinolin-4-ol 
• 1021912-69-5 5-[7-chloro-3-(3,5-dimethylphenyl)-4-{2-[(2R)-piperidin-2-yl]ethoxy}quinolin-6-yl]pyridin-2(1H)-one 
• 1276063-77-4 7-chloro-3-(3,5-dimethylphenyl)-4-{2-[(2R)-piperidin-2-yl]ethoxy}-6-(pyridin-3-yl)quinoline 
• 1021913-08-5 C₃₃H₃₉ClN₄O₃ 
• 1032816-26-4 C₃₆H₄₀ClN₃O₄ 

Relevant articles and documents

CHEMICAL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula:wherein R 1 , R 2 , R 3 and Z are as defined herein, and methods of making and using the same.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Design, synthesis, and evaluation of novel 3,6-diaryl-4- aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2

Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions

Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropria

SOMATOSTATIN AGONISTS

This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy,